Prevalence and seroprevalence of high-risk human papillomavirus infection

Obstetrics and Gynecology

Volumn 116, Issue 4, 2010, Pages 932-940

  Kim, Min A ^b   Oh, Jin Kyoung ^b   Chay, Doo Byung ^b   Park, Dong Choon ^b   Kim, Seok Mo ^b   Kang, Eun Suk ^b   Kim, Jae Hoon ^a   Cho, Chi Heum ^b   Shin, Hai Rim ^b   Seo, Kyung ^b  

^a Yonsei University College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS DNA; VIRUS VACCINE;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HYBRIDIZATION; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SERODIAGNOSIS; SEROPREVALENCE; SEXUAL BEHAVIOR; VACCINATION; VERRUCA VULGARIS; WART VIRUS; AGE DISTRIBUTION; CONFIDENCE INTERVAL; KOREA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CONFIDENCE INTERVALS; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; KOREA; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 77957235992     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181edbeba     Document Type: Article

References (30)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8. (Pubitemid 127695953)
2. HPV and cervical cancer in the world: 2007 report. Vaccine 2007;25(suppl 3):C1-230.
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
4. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papil-lomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527 (Pubitemid 36159887)
6. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13:110-116
7. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006;194:1044-1057
8. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-476
9. Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003;187:1246-1256
10. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-1919.
11. Clifford GM, Shin HR, Oh JK, Waterboer T, Ju YH, Vac-carella S, et al. Serologic response to oncogenic human papil-lomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16:1874-1879
12. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003;103:413-421 (Pubitemid 36076436)
13. Kim CJ, Kim BG, Kim SC, Kim YT, Kim YM, Park SY, et al. Sexual behavior of Korean young women: preliminary study for the introducing of HPV prophylactic vaccine. Korean J Gynecol Oncol 2007;18:209-218
14. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003;10:108-115
15. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005;12:959-969
16. Joo WD, Kim SH, Kim DY, Suh DS, Kim JH, Kim YM, et al. Prevalence of human papillomavirus infection in Korean women: risks of abnormal Pap smear and cervical neoplasia. Korean J Gynecol Oncol Colposc 2004;15:309-316
17. Oh JK, Franceschi S, Kim BK, Kim JY, Ju YH, Hong EK, et al. Prevalence of human papillomavirus and Chlamydia tracho-matis infection among women attending cervical cancer screening in the Republic of Korea. Eur J Cancer Prev 2009;18:56-61.
18. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-819
19. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillo-mavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-474
20. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-420
21. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-1816
22. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24(suppl 1):S1-15.
23. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, et al. Seroprevalence of human papillomavirus-16,-18,-31, and-45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003;89:1248-1254
24. Newall AT, Brotherton JM, Quinn HE, McIntyre PB, Backhouse J, Gilbert L, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008;46:1647-1655
25. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009;200:1059-1067
26. Skjeldestad FE, Mehta V, Sings HL, Ovreness T, Turpin J, Su L, et al. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008;87:81-88
27. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer 2007;97:989-991
28. Chen CJ, Viscidi RP, Chuang CH, Huang YC, Chiu CH, Lin TY. Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination. J Clin Virol 2007; 38:126-130
29. Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjar-gal D, Avirmed D, et al. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev 2008;17:1731-1738
30. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-1957.